(Q32055123)

6 July 2017

0 references

Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation (English)

1 reference

6 July 2017

1 reference

1 reference

1 reference

Khan IA

1

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

Journal of the American College of Cardiology

6 July 2017

published in

1 reference

6 July 2017

volume

37

1 reference

6 July 2017

issue

2

1 reference

6 July 2017

page(s)

542-547

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

6 July 2017

1 reference

7 January 2021

Atrial fibrillation. Problems in Management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Atrial fibrillation: a review of mechanism, etiology, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Short-term effect of atrial fibrillation on atrial contractile function in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Rhythm management in atrial fibrillation--with a primary emphasis on pharmacological therapy: Part 2

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Clinical course of recent-onset atrial fibrillation treated with oral propafenone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

The multiple modes of action of propafenone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Propafenone: a promising new antiarrhythmic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Clinical pharmacokinetics of propafenone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

In vitro protein binding of propafenone and 5-hydroxypropafenone in serum, in solutions of isolated serum proteins, and to red blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Severe reactive airways disease induced by propafenone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Congestive heart failure induced by six of the newer antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug. Comparison of spirometry with methacholine challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901116-5

7 January 2021

10.1016/S0735-1097(00)01116-5

Identifiers

DOI

1 reference

6 July 2017

1 reference